The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow [14]

W. Ingram*, N. C. Lea, J. Cervera, U. Germing, P. Fenaux, B. Cassinat, J. J. Kiladjian, J. Varkonyi, P. Antunovic, N. B. Westwood, M. J. Arno, A. Mohamedali, J. Gaken, T. Kontou, B. H. Czepulkowski, N. A. Twine, J. Tamaska, J. Csomer, S. Benedek, N. Gattermann & 5 others E. Zipperer, A. Giagounidis, Z. Garcia-Casado, G. Sanz, Ghulam J. Mufti

*Corresponding author for this work

Research output: Contribution to journalLetter

79 Citations (Scopus)
Original languageEnglish
Pages (from-to)1319-1321
Number of pages3
JournalLeukemia
Volume20
Issue number7
DOIs
Publication statusPublished - Jul 2006
Externally publishedYes

Cite this

Ingram, W., Lea, N. C., Cervera, J., Germing, U., Fenaux, P., Cassinat, B., ... Mufti, G. J. (2006). The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow [14]. Leukemia, 20(7), 1319-1321. https://doi.org/10.1038/sj.leu.2404215